Substituent Groups

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 431-463

  Bazzini, Patrick ^a   Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957529543     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00020-2     Document Type: Chapter

References (105)

1. Taylor, J. The topliss approach-opinion of an industrial scientist on QSAR methods. Lecture Given at the Louis Pasteur University .Stasbourg: New york, 1984. March 8.
2. Rekker R.F., Mannhold R. Calculation of Drug Lipophilicity 1992, Verlag VCH, Weinheim.
3. Witt K.A., Davis T.P. CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J 2006, 8(1):E76-E88.
4. Ooms F., Wouters J., Oscari O., Happaerts T., Bouchard G., Carrupt P.A., Testa B., Lambert D.M. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. J. Med. Chem. 2002, 45(9):1748-1756.
5. Gaillard P., Carrupt P.A., Testa B., Boudon A. Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J. Comput. Aided Mol. Des. 1994, 8(2):83-96.
6. Ginnings P., Baum R. Aqueous solubilities of the isomeric pentanols. J. Am. Chem. Soc. 1937, 59:1111-1113.
7. Nemethy G. Hydrophobic interactions. Angew. Chem. Int. Ed. Engl. 1967, 6(3):195-206.
8. Hansch C., Anderson S.M. The effect of intramolecular hydrophobic bonding on partition coefficients. J. Org. Chem. 1967, 32:2583-2586.
9. Gilligan D., Plummer N. Comparative solubilities of sulfadiazine, sulfamerazine and sulfamethazine and their N4-acetyl derivatives at varying pH levels. Proc. Soc. Exp. Biol. Med. 1943, 53:142-145.
10. Albert A. Selective Toxicity 1979, Chapman & Hall, London, p 41.
11. Harms A.F., Nauta W.T. The effects of alkyl substitution in drugs- I. Substituted dimethylaminoethyl benzhydryl ethers. J. Med. Pharm. Chem. 1960, 2:57-77.
12. Durant G.J., Ganellin C.R., Parsons M.E. Chemical differentiation of histamine H1- and H2-receptor agonists. J. Med. Chem. 1975, 18(9):905-909.
13. Reggio P., Topiol S., Weinstein H. Molecular determinants for the agonist activity of 2-methylhistamine and 4-methylhistamine at H2-receptors. J. Med. Chem. 1986, 29(11):2412-2415.
14. Velluz L. La stucture nor-stéroïde. .Actualités Pharmacologiques, 1961, 221-243. Masson & Cie, Paris. R. Hazard, J. Cheymol (Eds.).
15. Wermuth C.G., Schwartz J., Leclerc G., Garnier J.P., Rouot B. Communication préliminaire: conformation de la clonidine et hypotheses sur son interaction avec un récepteur α -adrénergique. Eur. J. Med. Chem. 1973, 8:115-116.
16. Perlman S., Costa-Neto C.M., Miyakawa A.A., Schambye H.T., Hjorth S.A., Paiva A.C., Rivero R.A., Greenlee W.J., Schwartz T.W. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. Mol. Pharmacol. 1997, 51(2):301-311.
17. Chu K.C. The quantitative analysis of structure-activity relationships. The Basis of Medicinal Chemistry/Burger's Medicinal Chemistry 1980, Vol. I:393-418. John Wiley & Sons, New York. M.E. Wolf (Ed.).
18. van de Waterbeemd H., el Tayar N., Carrupt P.A., Testa B. Pattern recognition study of QSAR substituent descriptors. J. Comput. Aided Mol. Des. 1989, 3(2):111-132.
19. Ganellin C.R. Conformation of histamine derivatives. 3. A relationship between conformation and pharmacological activity. J. Med. Chem. 1973, 16(6):620-623.
20. Paiva T.B., Tominaga M., Paiva A.C. Ionization of histamine, N -acetylhistamine, and their iodinated derivatives. J. Med. Chem. 1970, 13(4):689-692.
21. Andersson S.H., Lindgren A., Postlind H. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Metab. Dispos. 1998, 26(6):528-535.
22. Herz J.E., Swaminathan S., Pinkerton F.D., Wilson W.K., Schroepfer G.J. Inhibitors of sterol synthesis. A highly efficient and specific side-chain oxidation of 3 beta-acetoxy-5 alpha-cholest- 8(14)-en-15-one for construction of metabolites and analogs of the 15-ketosterol. J. Lipid Res. 1992, 33(4):579-598.
23. Roemer D., Beuscher H.H., Hill R.C., Pless J., Bauer W., Cardinaux F., Closse A., Hauser D., Huguenin R. A synthetic enkephalin analogue with prolonged parenteral and oral activity. Nature 1977, 268:547-549.
24. Plattner J.J., Norbeck D.W. Obstacles to drug development from peptide leads. D rug Discovery Technologies 1990, 92-126. Ellis Horwood Limited, Chichester. C.R. Clark, W.H. Moos (Eds.).
25. Fauchère J.L. Elements for the rational design of peptide drugs. Adv. Drug Res. 1986, Vol. 1:29-69. Academic Press, London. B. Testa (Ed.).
26. Gee K.W., McCauley L.D., Lan N.C. A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. C rit. Rev. Neurobiol. 1995, 9(2-3):207-227.
27. Carter R.B., Wood P.L., Wieland S., Hawkinson J.E., Belelli D., Lambert J.J., White H.S., Wolf H.H., Mirsadeghi S., Tahir S.H., Bolger M.B., Lan N.C., Gee K.W. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3betamethyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J. Pharmacol. Exp. Ther. 1997, 280(3):1284-1295.
28. Patrick G.L. The opium analgesics. An Introduction to Medicinal Chemistry 1995, 250-254. Oxford University Press, Oxford. 1st Edition.
29. Aquino C.J., Armour D.R., Berman J.M., Birkemo L.S., Carr R.A., Croom D.K., Dezube M., Dougherty R.W., Ervin G.N., Grizzle M.K., Head J.E., Hirst G.C., James M.K., Johnson M.F., Miller L.J., Queen K.L., Rimele T.J., Smith D.N., Sugg E.E. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin(CCK-A) receptor agonist activity. 1. Optimization of the agonist " trigger ". J. Med. Chem. 1996, 39(2):562-569.
30. Tute M.S. Principles and practice of Hansch analysis: a guide to structure-activity correlation for the medicinal chemist. A dvan. Drug Res. 1971, Vol. 6:1-77. Academic Press, London. N.J. Harper, A.B. Simmonds (Eds.).
31. Hansch C., Anderson S.M. The structure-activity relationship in barbiturates and its similarity to that in other narcotics. J. Med. Chem. 1967, 10:745-753.
32. Martin Y.C. Quantitative Drug Design: A Critical Introduction 1978, Marcel Dekker, Inc., New York.
33. Dawson M.I., Hobbs P.D., Derdzinski K., Chan R.L., Gruber J., Chao W.R., Smith S., Thies R.W., Schiff L.J. Conformationally restricted retinoids. J. Med. Chem. 1984, 27(11):1516-1531.
34. Lindamood C., Cope F.O., Dillehay D.L., Everson M.P., Giles H.D., Lamon E.W., McCarthy D.J., Sartin J.L., Hill D.L. Pharmacological and toxicological properties of arotinoids SMR-2 and SMR-6 in mice. Fundam. Appl. Toxicol. 1990, 14(1):15-29.
35. Rigas J.R., Dragnev K.H. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 2005, 10(1):22-33.
36. Lednicer D., Mitscher L.A., Georg G.I. The Organic Chemistry of Drug Synthesis 1990, Vol. 4. John Wiley & Sons, New York, p. 11.
37. Rizzo R.C., Wang D., Tirado-Rives J., Jorgensen W.L. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computational resistance profiles. J. Am. Chem. Soc. 2000, 122(51):12898-12900.
38. Ray A.S., Yang Z., Chu C.K., Anderson K.S. Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. A ntimicrob. Agents Chemother. 2002, 46(3):887-891.
39. Bai D.L., Tang X.C., He X.C., Huperzine A. a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 2000, 7(3):355-374.
40. Cussac M., Pierre J.L., Boucherle A., Favier F. Intérêt des derives du cyclopropane en Chimie Thérapeutique. Ann. Pharm. Fr. 1975, 33:513-529.
41. Marivet M.C., Bourguignon J.J., Lugnier C., Mann A., Stoclet J.C., Wermuth C.G. Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J. Med. Chem. 1989, 32:1450-1457.
42. Trivedi B.K., Holmes A., Stoeber T.L., Blankley C.J., Roark H.W., Picard J.A., Shaw M.K., Essenburg A.D., Stanfi R.L., Krause B.R. Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents. J. Med. Chem. 1993, 36:3300-3307.
43. Sexton W.A. Chemical Constitution and Biological Activity 1963, E. & F. N. Spon Ltd., London, p. 103. 3rd Edition.
44. Craig P.N. Guidelines for drug and analog design. The Basis of Medicinal Chemistry-Burger's Medicinal Chemistry, 4th ed. 1980, Vol. I:331-348. John Wiley & Sons, New York. M.E. Wolf (Ed.).
45. Hobbs J.B. Purine and pirimidine targets. Comprehensive Medicinal Chemistry 1990, 299-331. Pergamon Press, Oxford. P.G. Sammes (Ed.).
46. Manfredini S., Baraldi P.G., Bazzanini R., Marangoni M., Simoni D., Balzarini J., De Clercq E. Synthesis and cytotoxic activity of 6-vinyl- and 6-ethynyluridine and 8-vinyl-and 8-ethynyladenosine. J. Med. Chem. 1995, 38(1):199-203.
47. Rancourt J., Cameron D.R., Gorys V., Lamarre D., Poirier M., Thibeault D., Llinas-Brunet M. Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position. J. Med. Chem. 2004, 47(10):2511-2522.
48. Burger M.T., Lin X., Chu D.T., Hiebert C., Rico A.C., Seid M., Carroll G.L., Barker L., Huh K., Langhorne M., Shawar R., Kidney J., Young K., Anderson S., Desai M.C., Plattner J.J. Synthesis and antibacterial activity of novel C12 vinyl ketolides. J. Med. Chem. 2006, 49(5):1730-1743.
49. Browning E. Toxicity and Metabolism of Industrial Solvents 1965, Elsevier, New York, pp. 377-331, pp. 401-411.
50. Scholtan W., Sy L. Kolloid-chemische Eigenschaften eines neuen Kurznarkotikums. Teilgewicht der Mizelle und Verteilungsgleichgewicht des Wirkstoffes. (Colloidal chemical properties of a new short-acting anesthetic. Particle weight of the micelle and distribution equilibrium of the active compound.). A rzneimit.-Forsch. 1966, 16:679-691.
51. Rosen J., Miner J.N. The search for safer glucocorticoid receptor ligands. Endocr. Rev. 2005, 26(3):452-464.
52. Milne G.M., Johnson M.R. Narcotic antagonists and analgesics. Annu. Rep. Med. Chem. 1967, Vol. 11:23-32. Academic Press, New York. F.H. Clarke (Ed.).
53. Culvenor C.C.J., Dann A.T., Dick A.T. Alkylation as the mechanism by which the hepatotoxic pyrrolizidine alkaloids act on cell nuclei. Nature 1962, 195:570-573.
54. Sterling J., Herzig Y., Goren T., Finkelstein N., Lerner D., Goldenberg W., Miskowski I., Molnar S., Rantal F., Tamas T., Toth G., Zagyva A., Zekany A., Finberg J., Lavian G., Gross A., Friedman R., Razin M., Huang W., Krais B., Chorev M., Youdim M.B., Weinstock M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 2002, 45(24):5260-5279.
55. Cristofoli W.A., Wiebe L.I., De Clercq E., Andrei G., Snoeck R., Balzarini J., Knaus E.E. 5-Alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. J. Med. Chem. 2007, 50(12):2851-2857.
56. Madar D.J., Kopecka H., Pireh D., Yong H., Pei Z., Li X., Wiedeman P.E., Djuric S.W., Von Geldern.T.W., Fickes M.G., Bhagavatula L., McDermott T., Wittenberger S., Richards S.J., Longenecker K.L., Stewart K.D., Lubben T.H., Ballaron S.J., Stashko M.A., Long M.A., Wells H., Zinker B.A., Mika A.K., Beno D.W., J .Kempf-Grote A., Polakowski J., Segreti J., Reinhart G.A., Fryer R.M., Sham H.L., Trevillyan J.M. Discovery of 2-[4- { { 2-(2 S ,5 R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2- oxoethyl]amino]-4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. J. Med. Chem. 2006, 49(21):6416-6420.
57. Lee S.J., Konishi Y., Yu D.T., Miskowski T.A., Riviello C.M., Macina O.T., Frierson M.R., Kondo K., Sugitani M., Sircar J.C., et al. Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities. J. Med. Chem. 1995, 38(18):3547-3557.
58. Beart P.M., Uhr M.L., Johnston G.A.R. Inhibition of GABA transaminase activity by 4-aminotetrolic acid. J. Neurochem. 1972, 19:1855-1861.
59. Stutz A., Petranyi G. Synthesis and antifungal activity of (E)- N - (6,6-dimethyl-2-hepten-4-ynyl)- N -methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity. J. Med. Chem. 1984, 27(12):1539-1543.
60. Nussbaumer P., Leitner I., Mraz K., Stutz A. Synthesis and structure- activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function. J. Med. Chem. 1995, 38(10):1831-1836.
61. Schmitt J. Sur un nouveau myorelaxant de la classe des benzodiazépines: le tétrazepam. Eur. J. Med. Chem. 1967, 2:254-259.
62. Fryer R.I., Zhang P., Rios R., Gu Z.-Q., Basile A.S., Skolnick P. Structure-activity relationship studies at the benzodiazepine receptor (BZR): a comparison of the substituent effects of pyrazoloquinolinone analogs. J. Med. Chem. 1993, 36:1669-1673.
63. Bondi A. van der Waals volumes and radii. J. Phys. Chem. 1964, 68(3):441-451.
64. Taylor J.B., Kennewell P.D. Introductory Medicinal Chemistry 1981, Ellis Horwood Ltd., Chichester, p. 89.
65. Newman A.H., Allen A.C., Izenwasser S., Katz J. Novel 3 α - (diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J. Med. Chem. 1994, 37:2258-2261.
66. MacLeod A.M., Merchant K.J., Cascieri M.A., Sadowski S., Ber E., Swain C.J., Baker R. N -acyl- l -tryptophan benzyl esters: potent substance P receptor antagonists. J. Med. Chem. 1994, 36:2044-2045.
67. Gee K.W., Yamamura H.I. A novel pyrazoloquinoline that interacts with brain benzodiazepine receptors: characterization of some in vitro and in vivo properties of CGS 9896. L ife Sci 1982, 30:2245-2252.
68. B receptors in mammalian function 1990, John Wiley & Sons, Chichester.
69. Katritzky A.R., Dobchev D.A., Fara D.C., Hur E., Tamm K., Kurunczi L., Karelson M., Varnek A., Solov'ev V.P. Skin permeation rate as a function of chemical structure. J. Med. Chem. 2006, 49(11):3305-3314.
70. C. Hansch, A. Leo, D. Hoekman, Exploring QSAR: Hydrophobic, Electronic and Steric Constants, In: American Colloborative Chemical Society. (Ed.), ACS Professionnal Reference Books, Washington, DC, 1995.
71. Lide D.R. CRC Handbook of Chemistry and Physics 2005, CRC Press, Boca-Raton, FL. 86th Edition.
72. Buu-Hoï N.P. Les dérivés organiques du fluor d'intérêt pharmacologique. Progress in Drug Research 1961, Vol. 3:9-74. Birkhäuser Verlag, Basel. E. Jucker (Ed.).
73. Razgulin A.V., Mecozzi S. Binding properties of aromatic carbonbound fluorine. J. Med. Chem. 2006, 49(26):7902-7906.
74. Chen J., Hwang D.J., Bohl C.E., Miller D.D., Dalton J.T. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 2005, 312(2):546-553.
75. Wu D., Wu Z., Yang J., Nair V.A., Miller D.D., Dalton J.T. Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metab. Dispos. 2006, 34(3):483-494.
76. R. Drugs Fut 1998, 23:1234-1235. Anonymous.
77. Rosi D., Peruzzotti G., Dennis E.W., Berberian D.A., Freele H., Archer S. A new, active metabolite of " miracil D ". N ature 1965, 208:1005-1006.
78. Wermuth C.G. Aminopyridazines-an alternative route to potent muscarinic agonists with no cholinergic syndrome. II Farmaco 1993, 48:253-274.
79. Cappelli A., Giuliani.G., Pericot Mohr Gl G., Gallelli A., Anzini M., Vomero S., Cupello A., Scarrone S., Matarrese M., Moresco R.M., Fazio F., Finetti F., Morbidelli L., Ziche M. A non-peptide NK1 receptor agonist showing subpicomolar affinity. J. Med. Chem. 2004, 47(6):1315-1318.
80. Ganellin C.R., Roberts S.M. Medicinal Chemistry, the Role of Organic Chemistry in Drug Research 1993, Academic Press, London. 2 Edition.
81. Avendano Lopez M.C. Drug optimization by molecular manipulation. Meth. Find. Exp. Clin. Pharmacol. 2002, 24(Suppl. A):9-11.
82. Klaassen C.D. Heavy metals and heavy-metal antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1990, 1592-1614. Pergamon Press, New York. A. Goodman, T.W. Rall Gilman, A.S. Nies, P. Taylor (Eds.).
83. Evans D.C., O'Connor D., Lake B.G., Evers R., Allen C., Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. D rug Metab. Dispos. 2003, 31(7):861-869.
84. Bromidge S.M., Brown A.M., Clarke S.E., Dogson K., Gager T., Grassam H.L., Jeffrey P.M., Joiner G.F., King F.D., Middlemiss D.N., Moss S.F., Newman H., Riley G., Routledge C., Wyman P. 5-Chloro- N -(4-methoxy-3-piperazin- 1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT 6 receptor antagonist. J. Med. Chem. 1999, 42:202-205.
85. Abreu, M. E., Rzeszotarski, W., Kyle, D.J., Hiner, R. Preparation of oxopyrazolinyl thiocyanate and bis(oxopyrazolinyl)disulfides as corticotropin-releasing factor antagonist. US Patent 5063245 A, to Nova Pharmaceutical Corporation, 1991.
86. Szajnman S.H., Yan W., Bailey B.N., Docampo R., Elhalem E., Rodriguez J.B. Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation. J.Med.Chem. 2000, 43:1826-1840.
87. Stahl P.H., Wermuth C.G. Pharmaceutical Salts 2002, Helvetica Chimica Acta-John Wiley & Sons, Zürich.
88. Jirousek L., Pritchard E. On the chemical iodination of tyrosine with protein sulfenyl iodide and sulfenyl periodide derivatives. Biochim. Biophys. Acta. 1971, 243:230-238.
89. Haynes R.C. Thyroid and Antithyroid Drugs. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1990, 1361-1383. Pergamon Press, New York. 8 Edition. A. Goodman, T.W. Rall Gilman, A.S. Nies, P. Taylor (Eds.).
90. Montoro J., Sastre J., Bartra J., del Cuvillo A., Davila I., Jauregui I., Mullol J., Valero A.L. Effect of H1 antihistamines upon the central nervous system. J. Invest. Allergol. Clin. Immunol. 2006, 16(Suppl. 1):24-28.
91. Chen C., Hanson E., Watson J.W., Lee J.S. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab. Dispos. 2003, 31(3):312-318.
92. Remy D.C., Britcher S.F., King S.W., Anderson P.S., Hunt C.A., Randall W.C., Bélanger P., Atkinson J.G., Girard Y., Rooney C.S., Fuentes J.J., Totaro J.A., Robinson J.L., Risley E.A., Williams M. Synthesis and receptor binding dtudies relevant to the neuroleptic activities of some 1-methyl-4-piperidylene-9-substituted-pyrrolo[2,1- b ] [3]benzazepine derivatives. J. Med. Chem. 1983, 26:974-980.
93. Bookser B.C., Kasibhatla S.R., Erion M.D. AMP deaminase inhibitors. 4. Further N3-substituted coformycin aglycon analogues: N3-alkylmalonates as ribose 5'-monophosphate mimetics. J. Med. Chem. 2000, 43(8):1519-1524.
94. Duncia J.V., Chiu A.T., Carini D.J., Gregory G.B., Johnson A.L., Price W.A., Wells G.J., Wong P.C., Calabrese J.C., Timmermans P.B. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem. 1990, 33(5):1312-1329.
95. Carini D.J., Duncia J.V., Aldrich P.E., Chiu A.T., Johnson A.L., Pierce M.E., Price W.A., Santella J.B., Wells G.J., Wexler R.R., et al. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N -(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J. Med. Chem. 1991, 34(8):2525-2547.
96. Owa T., Yoshino H., Okauchi T., Yoshimatsu K., Ozawa Y., Sugi N.H., Nagasu T., Koyanagi N., Kitoh K. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 1999, 42(19):3789-3799.
97. Andersen K.E., Braestrup C., Gronwald F.C., Jorgensen A.S., Nielsen E.B., Sonnewald U., Sorensen P.O., Suzdak P.D., Knutsen L.J. The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J. Med. Chem. 1993, 36(12):1716-1725.
98. Yunger L.M., Fowler P.J., Zarevics P., Setler P.E. Novel inhibitors of γ -aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. J. Pharmacol. Exp. Ther. 1984, 228:109-115.
99. Ali F.E., Bondinell W.E., Dandridge P.A., Frazee J.S., Garvey E., Girard G.R., Kaiser C., Ku T.W., Lafferty J.J., Moonsammy G.I., Oh.H.-J., Rush J.A., Stler P.E., Stringer O.D., Venslavsky J.W., Volpe B.W., Yunger L.M., Zircle C.L. Orally active and potent inhibitors of γ -aminobutyric acid uptake. J. Med. Chem. 1985, 28:653-660.
100. Falch E., Krogsgaard-Larsen.P. GABA uptake inhibitors. Syntheses and structure-activity studies on GABA analogues containing diarylbutenyl and diarylmethoxyalkyl N -substituents. Eur. J. Med. Chem. 1991, 26:69-78.
101. Pavia M.R., Lobbestael S.J., Nugiel D., Mayhugh D.R., Gregor V.E., Taylor C.P., Schwarz R.D., Brahce L., Vartanian M.G. Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake. J. Med. Chem. 1992, 35:4238-4248.
102. N'Goka.V., Schlewer G., Linget J.M., Chambon J.P., Wermuth C.G. GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative. J. Med. Chem. 1991, 34(8):2547-2557.
103. Wermuth C.G., Mann A., Schoenfelder A., Wright R.A., Johnson B.G., Burnett J.P., Mayne N.G., Schoepp D.D. (2 S ,4 S)- 2-amino-4-(4,4-diphenylbut-1-yl)- pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase. J. Med. Chem. 1996, 39(4):814-816.
104. Frolund B., Jorgensen A.T., Tagmose L., Stensbol T.B., Vestergaard H.T., Engblom C., Kristiansen U., Sanchez C., Krogsgaard-Larsen P., Liljefors T. Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J. Med. Chem. 2002, 45(12):2454-2468.
105. Elz S., Kramer K., Pertz H.H., Detert H., ter Laak A.M., Kühne R., Schunack W. Histaprodifens: Synthesis, Pharmacological in Vitro Evaluation and Molecular Modeling of a New Class of Highly Active and Selective Histamine H 1 Receptor Agonists. J .Med.Chem. 2000, 43:1071-1084.